Premium
Precore and core promoter mutants are associated with higher HBeAg seroconversion but low disease remission rates in HBV patients treated with nucleos(t)ide analogues
Author(s) -
Zoutendijk R.,
Sonneveld M. J.,
Reijnders J. G. P.,
Vuuren A. J.,
Biesta P.,
Hansen B. E.,
Boonstra A.,
Janssen H. L. A.
Publication year - 2013
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/jvh.12033
Subject(s) - seroconversion , hbeag , medicine , mutant , virology , gastroenterology , immunology , hepatitis b virus , biology , virus , gene , hbsag , genetics
Summary HBeAg seroconversion in HBV patients is considered an important event. We determined precore (PC) and base core promoter ( BCP ) mutations in 137 HBeAg ‐positive nucleos(t)ide analogues ( NA ) treated patients by INNO ‐ LiPA HBV P re C ore assay (Innogenetics). The majority of patients with nongenotype A had PC / BCP mutants present at baseline ( P = 0.02). During 29 months of therapy, 45 patients achieved HBeAg seroconversion. Probability of HBeAg seroconversion was higher in patients with PC and/or BCP mutants ( P = 0.01). After HBeAg seroconversion, patients with BCP mutants had more HBeAg relapse ( P = 0.07), and PC mutants less often achieved HBV DNA < 2000 IU/ mL ( P = 0.07).